

**AMENDMENTS TO THE CLAIMS**

**1. (Previously presented)** An aqueous liquid preparation consisting essentially of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, and a water-soluble metal chloride in a light-stabilizing effective amount, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.

**2. (Cancelled)**

**3. (Previously presented)** The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from sodium chloride, potassium chloride and calcium chloride.

**4. (Cancelled)**

**5. (Previously presented)** The aqueous liquid preparation of claim 1, which is an acid addition salt of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid.

**6. (Original)** The aqueous liquid preparation of claim 5, wherein the acid addition salt is monobenzenesulfonate.

**7. (Previously presented)** The aqueous liquid preparation of claim 1, wherein the aqueous liquid preparation has a pH in the range of 4-8.5.

**8. (Previously presented)** The aqueous liquid preparation of claim 1, which is an eye drop.

**9. (Previously presented)** The aqueous liquid preparation of claim 1, which is a nasal drop.

**10. (Previously presented)** An aqueous eye drop comprising, in an aqueous solution, (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesulfonate, as the only active ingredient, and sodium chloride at not less than 0.2 w/v% and not more than 0.8 w/v% in a light-stabilizing effective amount.

**11. (Cancelled)**

**12. (Previously presented)** The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from alkali metal chlorides and alkaline earth metal chlorides.

**13. (Previously presented)** An aqueous eye drop consisting essentially of an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is light-stabilized with a water-soluble metal chloride, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.

**14. (New)** An aqueous liquid preparation consisting of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, a water-soluble metal chloride in a light-stabilizing effective amount, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%, benzalkonium chloride, sodium dihydrogenphosphate dihydrate, sodium hydroxide and water.